Key Points Rituximab exposure decreased as metabolic tumor volume increased, and correlated with metabolic response and survival. Rituximab dose could be individualized according to metabolic tumor volume to achieve optimal exposure and therefore optimal response.
No takes yet. Share an insight, caveat, or question.
Tout et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: